Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Dr. Reddy's Laboratories is a top-tier Indian pharma company built on global generics: North America is its largest market (complex generics and limited-competition launches, historically including lenalidomide), followed by India branded generics, Russia/CIS and Europe. It also has API manufacturing and a growing biosimilars and consumer-health push (including the acquired Haleon nicotine-replacement portfolio in international markets). Earnings are driven by US launch cadence and price erosion, plus steady India brand growth.
It is among India's top five pharma companies by revenue with one of the strongest US generics franchises.
Dr. Reddy's Laboratories Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 50, NIFTY 500, NIFTY HEALTHCARE, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Dr. Reddy's Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 50.41 | 67.89 | 335.22 |
| Book value / share (₹) | 457.86 | 406.80 | — |
| Return on equity | 11.0% | 16.7% | 19.7% |
| Return on capital employed | 10.6% | 18.8% | 22.1% |
| Operating margin | 13.0% | 21.0% | 23.1% |
| Net margin | 12.3% | 17.5% | 19.9% |
| EBITDA | ₹6,454 Cr | ₹8,547 Cr | ₹7,933 Cr |
| Free cash flow | ₹1,833 Cr | ₹1,203 Cr | ₹1,800 Cr |
| Total debt | ₹6,294 Cr | ₹4,185 Cr | ₹1,652 Cr |
| Debt to equity | 0.16 | 0.12 | 0.06 |
| Interest coverage | 11.8 | 24.2 | 37.8 |
| Current ratio | 1.80 | 1.92 | 2.59 |
| Shares outstanding | 83,50,00,000 | 83,40,00,000 | — |
Open the full income statement, balance sheet and cash flow for DRREDDY →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.